Industry News
Simoctocog alfa for haemophilia A: No suitable data
2/24/2015
Duration of direct comparator studies too short, study pool on comparator therapy incompleteSimoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A...
New HPV approved after international phase 2/3 trial involving Moffitt Cancer Center
2/24/2015
Vaccine protects boys and girls against nine HPV types known to cause cancer and other diseasesApproximately 12,000 women are diagnosed with cervical cancer each year in the United States and...
Simoctocog alfa for haemophilia A: No suitable data
2/24/2015
Duration of direct comparator studies too short, study pool on comparator therapy incompleteSimoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A...
New target for prostate cancer treatment discovered by Keck Medicine of USC researchers
2/24/2015
Keck Medicine of the University of Southern California (USC) scientists have found a promising new therapeutic target for prostate cancer.
Evolution may hold the key to more designer cancer drugs like Gleevec
2/24/2015
Brandeis University researchers pave the way for a new approach to rational drug designThis is the story of Abl and Src -- two nearly identical protein kinases whose evolution may hold the key to...
UW research shows sensor technology may help improve accuracy of clinical breast exams
2/24/2015
Sensor technology has the potential to significantly improve the teaching of proper technique for clinical breast exams (CBE), according to a new study by researchers at the University of Wisconsin...
Women back idea of more breast screens for those at high risk of cancer in the UK
2/24/2015
Most women (85 per cent) would back the idea of more frequent breast screening if they are at higher genetic risk of developing breast cancer, according to research* published by The Breast.
New target for prostate cancer treatment discovered by Keck Medicine of USC researchers
2/24/2015
Keck Medicine of the University of Southern California (USC) scientists have found a promising new therapeutic target for prostate cancer.
Evolution may hold the key to more designer cancer drugs like Gleevec
2/24/2015
Brandeis University researchers pave the way for a new approach to rational drug designThis is the story of Abl and Src -- two nearly identical protein kinases whose evolution may hold the key to...
NICE research misses the point of healthcare funding
2/23/2015
Responding to the publication of Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold by the Centre for Health Economics, Paul Catchpole...